Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
Phase 3
Completed
- Conditions
- Hodgkin Disease
- Interventions
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00038558
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
Phase 2
Completed
- Conditions
- Lymphoma, B-Cell
- Interventions
- Drug: PS341 (Bortezomib)
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00038571
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00038493
- Locations
- 🇺🇸
UTMD Anderson Cancer Center, Houston, Texas, United States
Study of Vioxx and Radiation Therapy for Brainstem Glioma
Phase 1
Terminated
- Conditions
- GliomaBrain Neoplasms
- Interventions
- Drug: Vioxx
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00038389
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00038402
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
Phase 2
Completed
- Conditions
- Lymphoma, T-CellHematologic NeoplasmsMycosis Fungoides
- Interventions
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT00038376
- Locations
- 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
Phase 1
Completed
- Conditions
- GliomaBrain Neoplasms
- Interventions
- Drug: DTI-015
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00038441
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach
Phase 1
Terminated
- Conditions
- Leukemia, Lymphocytic, Chronic
- Interventions
- Biological: CLL vaccine using DNA plasmid vector
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00038415
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Thalidomide for Multiple Myeloma
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00038233
- Locations
- 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
Phase 2
Terminated
- Conditions
- Ewing's Sarcoma
- Interventions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00038142
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath